Table 3.
Univariate and multivariable proportional hazards model for overall survival for circulating tumor cell count before chemotherapy (n = 2026)*
| Variable | Univariate Analysis | Multivariable Analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR 95% CI | P | |
| CTCs in blood, negative vs positive | 2.447 (1.491 to 4.015) | .0004 | 2.177 (1.320 to 3.588) | .002 |
| Hormone receptor status, positive vs negative | 3.414 (2.098 to 5.556) | <.0001 | 2.997 (1.763 to 5.095) | <.0001 |
| Lymph node involvement, N0 vs N1–3 | 2.465 (1.290 to 4.709) | .006 | 4.254 (2.182 to 8.293) | <.0001 |
| Grading, G1 vs G2–3 | 4.097 (2.271 to 7.392) | <.0001 | 3.549 (1.864 to 6.760) | .0001 |
| Tumor size, T1 vs T2–4 | 2.969 (1.618 to 5.446) | .0004 | 2.665 (1.441 to 4.930) | .002 |
| Menopausal status, pre vs post | 1.990 (1.157 to 3.421) | .013 | 1.518 (0.876 to 2.629) | .14 |
| Histology, lobular/mixed vs ductal | 2.020 (0.923 to 4.423) | .08 | 1.262 (0.559 to 2.850) | .58 |
* Cox proportional hazards models. All statistical tests were two-sided. CI = confidence interval; CTC = circulating tumor cell; HR = hazard ratio.